Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)

Trial Profile

Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms TAXT-XRT
  • Most Recent Events

    • 24 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 19 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top